CSF α-synuclein, tau, and amyloid β in Parkinson's disease

The Lancet Neurology

Volumn 10, Issue 8, 2011, Pages 681-

  Shi, Min ^a   Zhang, Jing ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; TAU PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT;

CEREBROSPINAL FLUID; COHORT ANALYSIS; DISEASE SEVERITY; GENETIC ASSOCIATION; HUMAN; LETTER; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; SENILE PLAQUE;

ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; HUMANS; PARKINSON DISEASE; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 79960353168     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70130-2     Document Type: Letter

References (10)

1. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011, 10:230-240.
2. Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011, 69:570-580.
3. Hong Z, Shi M, Chung KA, et al. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010, 133:713-726.
4. Montine TJ, Shi M, Quinn JF, et al. CSF Aβ42 and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010, 25:2682-2685.
5. Abdo WF, Bloem BR, Van Geel WJ, Esselink RA, Verbeek MM CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Neurobiol Aging 2007, 28:742-747.
6. Alves G, Bronnick K, Aarsland D, et al. CSF amyloid-β and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2010, 81:1080-1086.
7. Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009, 41:1308-1312.
8. Haass C, Selkoe DJ Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol 2007, 8:101-112.
9. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, La Ferla FM Synergistic Interactions between Aβ, tau, and α-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 2010, 30:7281-7289.
10. Tsigelny IF, Crews L, Desplats P, et al. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS One 2008, 3:e3135.